Prostate Cancer

Access ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.

Karim Fizazi discusses the key results presented on prostate cancer about the use of abiraterone in newly diagnosed high risk metastatic hormone-naive setting, a study of continued active drug post PSA progression and some interesting data about biomarkers research in prostate cancer.

Clinical Practice Guidelines